# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Eva Perón (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML025-SYN-TD
- Date: 1951-05-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lucía Barragán, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Review two weeks after completing chemoradiation and brachytherapy. **S**

## History of present illness

Ms. Perón returns two weeks after her last brachytherapy treatment. She completed 25 fractions of pelvic radiation and five weekly cisplatin doses without a break, then four brachytherapy treatments, finishing eight weeks after the start. The bladder infection in the third week cleared with nitrofurantoin. The diarrhea settled once radiation ended and she has not needed loperamide for two weeks; nausea stopped after the last cisplatin. She has no bleeding, only a light discharge. For the past ten days she has had about eight hot flashes a day, night sweats that wake her, and vaginal dryness. She has no ringing in the ears or numbness in her hands or feet. She is very tired but walks daily and is working mornings. She has kept seeing the social worker. **S**

| Element | Detail |
|---|---|
| Treatment | 45 Gy in 25 fractions with five weekly cisplatin doses, then four brachytherapy fractions, in eight weeks |
| Side effects | Diarrhea resolved; nausea gone; no ringing or numbness; tired |
| New symptoms | Hot flashes about eight a day, night sweats, vaginal dryness |
| Bleeding | None; light discharge |
| Scores | PHQ-9 7; GAD-7 6; pelvic pain 1 of 10 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; night sweats; no fever |
| Gastrointestinal | Negative | Bowels back to normal; no rectal bleeding |
| Genitourinary | Positive | Vaginal dryness and light discharge; no bleeding; no urinary symptoms |
| Endocrine | Positive | Hot flashes about eight a day |
| Neurological | Negative | No numbness, tingling, or ringing in the ears |
| Psychiatric | Negative | Tired but hopeful; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth once daily, with vitamin C-rich food or juice, apart from tea and dairy **S**
- Acetaminophen 500 mg oral tablet, one or two tablets by mouth every 6 hours when needed for pelvic pain, no more than 6 tablets a day **S**
- Estradiol 0.1 mg per day transdermal patch, one patch changed twice weekly **S**
- Progesterone 100 mg oral capsule, one capsule by mouth nightly, to protect any remaining endometrium while on estradiol **S**

## Allergies

- No known allergy **S**

## Objective

BP 104/66 mmHg; pulse 80 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 50.6 kg; BMI 18.6 kg/m². All vital signs are synthetic.

Hemoglobin: 11.2 g/dL (low); Creatinine: 0.8 mg/dL; eGFR: 101 mL/min/1.73 m²; Pelvic pain, worst in the past week (0 to 10): 1; PHQ-9: 7; GAD-7: 6; FSH: 72 m[IU]/mL (high); Estradiol: 14 pg/mL (low); Magnesium: 1.9 mg/dL. All results are synthetic.

## Change since baseline

- Hemoglobin: 9.4 g/dL (low) at baseline, 11.2 g/dL (low) at this visit **S**
- Pelvic pain, worst in the past week (0 to 10): 4 at baseline, 1 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Thin and tired; weight 50.6 kg; blood pressure 104/66 |
| Abdomen | Soft and non-tender |
| Skin | Mild darkening of the skin in the radiation field; no breakdown |
| Pelvic | Gentle speculum examination: radiation changes of the upper vagina; cervix smaller, without bleeding; no mass seen |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Squamous cell carcinoma of the cervix, FIGO 1943 stage IIB** (C53.9). Treatment completed as planned within eight weeks. Acute side effects have settled; no hearing loss or neuropathy after cisplatin; kidney function and magnesium normal (creatinine 0.8 mg/dL, eGFR 101, magnesium 1.9 mg/dL). The tumor already looks smaller. Response is judged by PET-CT and examination about three months after treatment. **S**
   - PET-CT about three months after treatment.
   - Vaginal dilator three times a week from now, with a water-based lubricant.
   - Gynecologic oncology review every three months for two years.
2. **Ovarian failure after pelvic radiation** (E89.41). Hot flashes, night sweats and vaginal dryness with FSH 72 mIU/mL and estradiol 14 pg/mL: ovarian failure from pelvic radiation, as she was told to expect. At 32, estrogen therapy relieves symptoms and protects bone and heart; cervical squamous cell carcinoma is not hormone-dependent. Because the uterus remains, a progestogen is added. **S**
   - Estradiol 0.1 mg patch twice weekly.
   - Progesterone 100 mg nightly.
   - Continue until about the usual age of menopause, reviewed yearly.
   - Report leg swelling, chest pain or sudden breathlessness.
3. **Acute cystitis** (N30.00). Resolved; the culture grew Escherichia coli sensitive to nitrofurantoin. **S**
   - No further action.
4. **Iron deficiency anemia** (D50.0). Hemoglobin 11.2 g/dL, rising. **S**
   - Continue ferrous sulfate; ferritin at the end of the course.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Treatment side effects (bowel, bladder, skin, nausea, hearing, nerve symptoms) | Weekly during treatment, then at each visit | Completed today | Diarrhea and nausea resolved; skin intact; no hearing loss or neuropathy |
| Laboratory | Kidney function (creatinine, eGFR) and magnesium for cisplatin | Before cisplatin, weekly during it, and after | Completed today | Creatinine 0.8 mg/dL, eGFR 101, magnesium 1.9 mg/dL |
| Laboratory | Blood count (hemoglobin, white cells, platelets) | About one month after starting oral iron, then every three months for a year; weekly during chemoradiation | Completed today | Hemoglobin 11.2 g/dL |
| Laboratory | Ovarian function (FSH, estradiol) | When menopause symptoms appear after pelvic radiation | Completed today | FSH 72 mIU/mL, estradiol 14 pg/mL: ovarian failure |
| Examination | Pelvic, speculum and rectovaginal examination | At diagnosis; every three to six months for two years after treatment | Completed today | Gentle speculum examination: cervix smaller; no mass seen |
| Imaging | FDG PET-CT | At staging; about three months after chemoradiation | Due | About three months after treatment |
| Survey | Pelvic pain score and analgesic safety (no anti-inflammatory painkillers with cisplatin) | Every visit | Completed today | 1 of 10 |
| Survey | PHQ-9 and GAD-7 | At diagnosis, before treatment, at mid-treatment, at the end of treatment, and in follow-up | Deferred | PHQ-9 7 and GAD-7 6 today. The mid-treatment measures were not done: the only visit here during treatment was the sick visit for cystitis, and the weekly oncology reviews did not record them. No harm resulted: scores fell from diagnosis to today, and the social worker saw her weekly. Corrective action: the social worker now records the PHQ-9 and GAD-7 at the mid-treatment review |
| Self-management | Vaginal dilator use | Starting two to four weeks after radiation, three times a week | Completed today | Taught today; three times a week |
| Medication safety | Hormone therapy safety (blood pressure, clot symptoms) and symptom control | At the start and every visit | Completed today | Blood pressure 104/66; no clot history; starts today |
| Referral | Survivorship care plan and gynecologic oncology follow-up | From the end of treatment | Completed today | Gynecologic oncology every three months for two years |

## Goal progress

- Diagnosis and stage explained to her directly, in Spanish, with time for questions, before any treatment decision. Outcome by 1951-03-02: Diagnosis given to her in person at the second visit and the stage at the third; she made the treatment and fertility decisions herself. **S**
- Hemoglobin 10 g/dL or more before radiation begins. Outcome by 1951-03-02: Hemoglobin 10.2 g/dL. **S**
- Chemoradiation and brachytherapy completed within eight weeks. Outcome by 1951-05-18: Completed in eight weeks, with five cisplatin doses. **S**
- No evidence of disease on PET-CT and examination three months after treatment. In progress; target 1951-08-17. **S**
- PHQ-9 below 5 by six months. In progress; target 1951-08-17. **S**

## Medication changes

- Started: Estradiol 0.1 mg per day transdermal patch, one patch changed twice weekly **S**
- Started: Progesterone 100 mg oral capsule, one capsule by mouth nightly, to protect any remaining endometrium while on estradiol **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (Version 1.2027), National Comprehensive Cancer Network
- Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update (2018), American Society of Clinical Oncology (Journal of Clinical Oncology)
- Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update (2023), American Society of Clinical Oncology (Journal of Clinical Oncology)
- CMID: Clinical Monitoring Intelligence Database, anemia monograph (2026), Aether Forge

## Follow-up

- Gynecologic oncology review in one month. PET-CT and review here about three months after treatment. **S**
- Next scheduled visit 1951-08-17: review three months after treatment: PET-CT response, examination, anemia, mood, and the follow-up plan. **S**
